For the Inventor, By the Inventor

Enter assignee name

Malvern, PA, United States of America

Endo Pharmaceuticals Inc.

Calculating rank

USPTO Granted Patents = 32

% Expired Patents = 28.1

CIPO Patents = 8

EPO Patents = 6

Trademarks = 41

Forward Citations = 411

Loading Chart...

Loading Chart...

66 inventors (with patents filed for the assignee):

Anand R Baichwal (11 out of 50 patents)

Philip A Goliber (6 out of 7 patents)

Thomas Sciascia (6 out of 13 patents)

4. Anthony E Carpanzano (6 out of 10 patents)

5. Donald Diehl (6 out of 7 patents)

6. Brian Vogler (6 out of 7 patents)

7. David Verbel (4 out of 12 patents)

8. Stanley Au (4 out of 5 patents)

9. Troy McCall (4 out of 5 patents)

10. Frank S Caruso (4 out of 23 patents)

11. Harry Ahdieh (3 out of 3 patents)

12. David Lee (3 out of 3 patents)

13. Roger Astbury Smith (3 out of 75 patents)

14. Huai-Hung D Kao (3 out of 15 patents)

15. Subramanya Hosahalli (2 out of 17 patents)

Core Competencies:

Oxymorphone

Nalbuphine

Sustained Release

Pain Management

Chronotherapeutic

Pharmaceutical Compositions

Neuropathic Pain

Xerostomia

Urinary Incontinence

Capsaicinoid

Drug Formulations

Manufacturing Processes

32 patents: Sort by Forward Citations

1. 11389443 - Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment (2022-07-19),

2. 10406106 - Sustained release formulations of nalbuphine (2019-09-10),

3. 10251908 - [object Object] (2019-04-09),

4. 10172798 - Sustained release formulation of nalbuphine (2019-01-08),

5. 10052344 - [object Object] (2018-08-21),

6. 9926328 - Crystalline, anhydrous forms of oxymorphone hydrochloride (2018-03-27),

7. 9820982 - Oxymorphone controlled release formulations (2017-11-21),

8. 9789103 - Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment (2017-10-17),

9. 9440986 - Crystalline, anhydrous forms of oxymorphone hydrochloride (2016-09-13),

10. 9351938 - Sustained release formulation of nalbuphine (2016-05-31),

11. 9278076 - Chronotherapeutic dosage forms (2016-03-08),

12. 9186330 - Sustained release formulation of nalbuphine (2015-11-17),

13. 9050163 - Urethral anastomosis device and method (2015-06-09),

14. 8808737 - Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment (2014-08-19),

15. 8771732 - Sustained release formulations of nalbuphine (2014-07-08),

Company Overview

Endo Pharmaceuticals Inc. is a specialty pharmaceutical company based in Malvern, Pennsylvania, focused on developing and commercializing innovative therapies for patients with unmet medical needs. The company specializes in pain management and urology, offering a range of prescription medications that address various health conditions. Endo is committed to advancing healthcare through research and development, leveraging its expertise in drug formulation and delivery to improve patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

32 Patents

#19 in Malvern, PA

#382 in Pennsylvania

#10,615 in US

#20,712 in the World

Malvern, PA, United States of America

Endo Pharmaceuticals Inc.

Forward Citations = 411

66 inventors:

Anand R Baichwal (11 out of 50 patents)

Philip A Goliber (6 out of 7 patents)

Thomas Sciascia (6 out of 13 patents)

4. Anthony E Carpanzano (6 out of 10 patents)

5. Donald Diehl (6 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Endo Pharmaceuticals Inc.. Retrieved from https://idiyas.com/company/endo-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…